Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast

BMC Clinical Pathology

Volumn 12, Issue , 2012, Pages

  Serce, Nuran ^a   Gnatzy, Annette ^a   Steiner, Susanne ^a   Lorenzen, Henning ^a   Kirfel, Jutta ^a   Buettner, Reinhard ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

DCIS; IDC; LSD1

Indexed keywords

ESTROGEN RECEPTOR; LYSINE SPECIFIC DEMTHYLASE 1; NUCLEAR PROTEIN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCORING SYSTEM; UPREGULATION;

EID: 84865296983     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-12-13     Document Type: Article

References (24)

1. LSD1 and the chemistry of histone demethylation. Culhane JC, Cole P, Chem Bio 2007 11 561 568 (Pubitemid 47588999)
2. The language of covalent histone modification. Strahl BD, Allis CD, Nature 2000 403 41 45 10.1038/47412 10638745 (Pubitemid 30038513)
3. Mechanisms involved in the regulation of histone lysine demethylases. Lan F, Nottke AC, Shi Y, Curr Opin Cell Biol 2008 20 3 316 325 10.1016/j.ceb.2008. 03.004 18440794
4. Regulation of LSD1 histone demethylase activity by associated factors. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y, Mol Cell 2005 19 857 864 10.1016/j.molcel.2005.08.027 16140033 (Pubitemid 41316679)
5. New roles of flavoproteins in molecular cell biology: Histone demethylase LSD1 and chromatin. Forneris F, Battaglioni E, Mattevi A, Binda C, FEBS 2009 276 4304 4312 10.1111/j.1742-4658.2009.07142.x
6. The lysine-specific demethylase 1 is required for cell proliferation in both p53-depended and -independend manners. Scoumanne A, Chen X, J Biol Chem 2007 282 15471 15478 10.1074/jbc.M701023200 17409384 (Pubitemid 47093261)
7. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y, Cell 2004 119 941 953 10.1016/j.cell.2004.12.012 15620353 (Pubitemid 40037608)
8. Phosphorylation of histone H3T6 by PKCI controls demethylation at histone H3K4. Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N, Müller JM, Greschik H, Kirfel J, Ji S, Kunowska N, Beisenherz-Huss C, Günther T, Buettner R, Schüle R, Nature 2010 464 792 796 10.1038/nature08839 20228790
9. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schüle R, Buettner R, Cancer Res 2006 66 23 11341 11347 10.1158/0008-5472.CAN-06-1570 17145880 (Pubitemid 46009965)
10. Lysine-specific demethylase 1 is strongly expressed in poor differentiated neuroblastoma: implications for therapy. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schüle R, Eggert A, Buettner R, Kirfel J, et al. Cancer Res 2009 69 2065 2071 19223552
11. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R, International Journal of Cancer 2011 128 3 574 586 10.1002/ijc.25349
12. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localilzed and advanced human bladder cancer. Kauffmann EC, Robinson BD, Downes MJ, Powell LG, Lee MM, Scherr DS, Gudas LJ, Mongan NP, Mol Carcinog 2011 50 12 931 944 10.1002/mc.20758. Epub 2011 Mar 11 21400613
13. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, Kirfel J, Carcinogenesis 2010 31 3 512 520 10.1093/carcin/bgp324 20042638
14. Biology of progesterone receptor loss in breast cancer and its implication for endocrine therapy. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV, J Clin Oncol 2005 23 30 7721 7735 10.1200/JCO.2005.09.004 16234531 (Pubitemid 46291836)
15. Carcinogen-induced alteration in normal human mammary epithelial cells. Bradley C, van der Meer R, Roodi N, Yan H, Chandrasekharan MB, Sun ZW, Mernaugh RL, Parl FF, Carcinogenesis 2007 28 10 2184 2192 10.1093/carcin/bgm100 17468514 (Pubitemid 47543380)
16. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Tavassoli FA, Devilee P, IARC Press, Lyon 2003
17. Recommendation for uniform definition of an immunoreactive score (IRS) for immunhistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Remmele W, Stegner HE, Pathologe 1987 8 3 138 140 3303008
18. Radiation therapy for ductal carcinoma in situ: a decision analysis. Punglia RS, Burstein HJ, Weeks JC, Cancer 2012 118 3 603 611 10.1002/cncr.26293. Epub 2011 Jun 30 21720992
19. Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Boughey JC, Gonzalez RJ, Bonner E, Kuerer HM, Oncologist 2007 12 11 1276 1287 10.1634/theoncologist.12-11-1276 18055847 (Pubitemid 350232601)
20. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF, Cancer 2011 117 1 39 47 10.1002/cncr.25399 20740500
21. Adjuvant hormonal therapy use among women with ductal carcinoma in situ. Lidauvais JC, Hwang ES, Karliner L, Nápoles A, Stewart S, Bloom J, Kaplan CP, J Womens Health (Larchmt) 2012 21 1 35 42 Epub 2011 Sep 8 10.1089/jwh.2011.2773
22. Ductal carcinoma in situ: trends in treatment over time in the US. Zujewski JA, Harlan LC, Morrell DM, Stevens JL, Breast Cancer Res Treat 2011 127 1 251 257 10.1007/s10549-010-1198-z 20931276
23. Histone H3 Lysine 4 Demethylation is a target of nonselective antidepressive medications. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R, Chemistry and Biology 2006 13 563 567 10.1016/j.chembiol.2006.05. 004 16793513
24. Sobin LH, Gospodarowicz MK, Wittekind C, UICC: TNM classification of malignant tumors Wiley-Blackwell, Oxford 7 2009